Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4255 - The role of comprehensive evaluation for clinical complete response in predicting pathologic complete response in patients treated with neoadjuvant chemoradiation for esophageal squamous cell carcinoma (ESCC)

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Pathology/Molecular Biology

Tumour Site

Oesophageal Cancer

Presenters

Hyeon-Su Im

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

H. Im1, J. Kang2, Y. Kim3, H.R. Kim3, J.H. Kim4, H. Jung5, G. Lee6, H.J. Song6, D.H. Kim6, K.D. Choi6, J.H. Lee6, J.Y. Ahn6, J. Ryu7, K. Cho8, S. Kim9, S.R. Park10

Author affiliations

  • 1 Department Of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 138-931 - Seoul/KR
  • 2 Department Of Oncology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 03181 - Seoul/KR
  • 3 Department Of Thoracic Surgery, Asan Medical Center, University of Ulsan College of Medicine, 05505 - seoul/KR
  • 4 Department Of Radiation oncology, Asan Medical Center, University of Ulsan College of Medicine, 05505 - seoul/KR
  • 5 Department Of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 138-931 - Seoul/KR
  • 6 Department Of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 05505 - seoul/KR
  • 7 Department Of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, 05505 - seoul/KR
  • 8 Department Of Pathology, Asan Medical Center, University of Ulsan College of Medicine, 05505 - seoul/KR
  • 9 Department Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 138-931 - Seoul/KR
  • 10 Department Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR
More

Resources

Abstract 4255

Background

Neoadjuvant chemoradiation (nCRT) followed by surgery is the preferred treatment for locally advanced ESCC. But a recent trial suggested close observation might be a reasonable option in patients achieving clinical complete response (CR) to nCRT. For this strategy, accurate clinical assessment for predicting pathologic CR (pCR) is essential. In NCCN guidelines PET/CT is recommend as response assessment, whereas endoscopy is optional after nCRT.

Methods

In 234 patients who received nCRT (46–50.4Gy) plus surgery for locally advanced ESCC at Asan Medical Center from 2007 to 2014, the performance of endoscopy and PET/CT which were done 4-8 weeks after nCRT for predicting pCR was evaluated. Metabolic CR (mCR) was defined as complete resolution of FDG uptake within all lesions, making them indistinguishable from surrounding tissue, and endoscopic CR (eCR) as no residual mucosal lesions except for scar change.

Results

pCR (ypT0N0) was achieved in 108 patients (46.2%), and ypT0N+ in 17 (7.3%). Among patients who underwent PET/CT (n = 231), mCR was obtained in 102 (44.2%), and non-mCR in 81 (35.1%), whereas metabolic response could not be assessed due to diffuse esophagitis in 48 (20.8%). The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of mCR for pCR was 56.6%, 46.4%, 58.8%, and 71.6%, respectively. Among patients who underwent endoscopy (n = 229), eCR was obtained in 42 (18.3%), and the sensitivity, specificity, PPV, and NPV of eCR for pCR only in primary tumor site (ypT0N+/-) was 29.5%, 94.4%, 85.7%, and 54.0%, respectively. When adding endoscopic response to metabolic response, the sensitivity, specificity, PPV, and NPV of clinical CR for pCR was 27.9%, 94.3%, 80.6%, and 60.5%, respectively, and the positive likelihood ratio for pCR was 4.9 (95% CI 2.2–10.6).

Conclusions

The addition of endoscopic evaluation to metabolic response after nCRT improved specificity and PPV for pCR compared to metabolic response alone, which could help in applying surveillance strategy without immediate surgery in patients achieving clinical CR after nCRT for ESCC.

Clinical trial identification

Legal entity responsible for the study

Asan Medical Center.

Funding

Asan Medical Center.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.